| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Cell Proliferation without Affecting Insulitis
* Division of Endocrinology, School of Medicine, Keio University, Tokyo, Japan; and
Department of Molecular Preventive Medicine, School of Medicine, University of Tokyo, Tokyo, Japan
We have shown that neutralization of IFN-inducible protein 10/CXCL10, a chemokine for Th1 cells, breaks Th1 retention in the draining lymph nodes, resulting in exacerbation in Th1-dominant autoimmune disease models induced by immunization with external Ags. However, there have been no studies on the role of CXCL10 neutralization in Th1-dominant disease models induced by constitutive intrinsic self Ags. So, we have examined the effect of CXCL10 neutralization using a type 1 diabetes model initiated by developmentally regulated presentation of 
cell Ags. CXCL10 neutralization suppressed the occurrence of diabetes after administration with cyclophosphamide in NOD mice, although CXCL10 neutralization did not significantly inhibit insulitis and gave no influence on the trafficking of effector T cells into the islets. Because both CXCL10 and CXCR3 were, unexpectedly, coexpressed on insulin-producing cells, CXCL10 was considered to affect mature and premature cells in an autocrine and/or paracrine fashion. In fact, CXCL10 neutralization enhanced proliferative response of cells and resultantly increased cell mass without inhibiting insulitis. Thus, CXCL10 neutralization can be a new therapeutic target for cell survival, not only during the early stage of type 1 diabetes, but also after islet transplantation.
This article has been cited by other articles:
|
|
 |
|
  B. Calderon, A. Suri, X. O. Pan, J. C. Mills, and E. R. Unanue IFN-{gamma}-Dependent Regulatory Circuits in Immune Inflammation Highlighted in Diabetes J. Immunol., November 15, 2008; 181(10): 6964 - 6974. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Martin, M. G. Grisotto, C. Canasto-Chibuque, S. L. Kunkel, J. S. Bromberg, G. C. Furtado, and S. A. Lira Islet Expression of M3 Uncovers a Key Role for Chemokines in the Development and Recruitment of Diabetogenic Cells in NOD Mice Diabetes, February 1, 2008; 57(2): 387 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rotondi, L. Chiovato, S. Romagnani, M. Serio, and P. Romagnani Role of Chemokines in Endocrine Autoimmune Diseases Endocr. Rev., August 1, 2007; 28(5): 492 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. N. Stiles, J. L. Hardison, C. S. Schaumburg, L. M. Whitman, and T. E. Lane T Cell Antiviral Effector Function Is Not Dependent on CXCL10 Following Murine Coronavirus Infection J. Immunol., December 15, 2006; 177(12): 8372 - 8380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Fiorina, M. J. Ansari, M. Jurewicz, M. Barry, V. Ricchiuti, R. N. Smith, S. Shea, T. K. Means, H. Auchincloss Jr., A. D. Luster, et al. Role of CXC Chemokine Receptor 3 Pathway in Renal Ischemic Injury J. Am. Soc. Nephrol., March 1, 2006; 17(3): 716 - 723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Shigihara, A. Shimada, Y. Oikawa, H. Yoneyama, Y. Kanazawa, Y. Okubo, K. Matsushima, E. Yamato, J.-i. Miyazaki, A. Kasuga, et al. CXCL10 DNA Vaccination Prevents Spontaneous Diabetes through Enhanced {beta} Cell Proliferation in NOD Mice J. Immunol., December 15, 2005; 175(12): 8401 - 8408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rhode, M. E. Pauza, A. M. Barral, E. Rodrigo, M. B. A. Oldstone, M. G. von Herrath, and U. Christen Islet-Specific Expression of CXCL10 Causes Spontaneous Islet Infiltration and Accelerates Diabetes Development J. Immunol., September 15, 2005; 175(6): 3516 - 3524. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
